SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amidst heightened market uncertainty driven by recent geopolitical rhetoric from the US administration regarding tariffs and Greenland, alongside concerns about the stability of the Japanese bond market. The community is sharply divided, with many predicting significant short-term downside, while others expect a swift market recovery after initial drops.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as discussions are dominated by escalating geopolitical tensions following former President Trump's threats of tariffs against European nations over Greenland. This news has triggered significant drops in futures, leading to polarized community sentiment: some foresee a 'bloody Tuesday,' while others confidently expect a quick 'V-shaped' recovery, anticipating aggressive 'buy the dip' action amid these trade concerns.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is actively trending as its move-to-earn crypto model, rewarding users for physical activity, gains renewed community interest amidst recent token burns aimed at boosting scarcity. Investors are discussing its long-term potential, pointing to staking opportunities and expanding Web3 ecosystem utility, with many urging others not to overlook its future growth.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is a top trending stock as analysts, including Wells Fargo, highlight its strong CPU leadership and expanding AI GPU portfolio as a top pick in the burgeoning data center market. The community is actively discussing AMD's strategic positioning as a key competitor to Nvidia, further bolstered by its significant direct infrastructure deal with Riot Platforms. This momentum underscores AMD's efforts to capture substantial AI infrastructure share amidst robust sector demand.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending downward amid heightened geopolitical tensions, primarily driven by US tariff threats against European countries in relation to Greenland, which has injected significant uncertainty into the broader market. The community is actively attributing this volatility to political actions, prompting widespread debate on Bitcoin's role as a safe-haven asset, especially as other commodities see increased interest. This has led to notable liquidations and a divided sentiment between those anticipating further declines and others viewing the dip as a prime buying opportunity.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is experiencing intense buzz driven by recent Saudi FDA approval for its Anktiva cancer treatment, particularly for non-small cell lung cancer, along with positive clinical trial results. The community is highly optimistic about the company's "no chemo/radiation" approach and the potential for a massive short squeeze, with Dr. Patrick Soon-Shiong's active engagement amplifying discussions around a paradigm shift in global cancer therapy.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is experiencing a significant surge to new all-time highs, propelled by escalating geopolitical tensions, including recent tariff threats against Europe and broader global instability. The community is actively discussing whether this rally reflects a critical flight to safety amidst concerns over the US dollar's strength and eroding confidence in fiat currencies, with many anticipating sustained upward momentum for precious metals.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending amid renewed uncertainty regarding H200 chip sales to China, with reports of blocked shipments fueling investor concern. This adds to broader market volatility stemming from escalating geopolitical tariff threats, prompting community discussion on the immediate impact versus the company's long-term AI leadership. While some see a buying opportunity fueled by NVIDIA's strong product pipeline, others remain cautious about potential market disruptions.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is drawing immense attention as renewed geopolitical interest in Greenland by former President Trump intensifies the focus on the island's vast rare earth deposits. The community is actively discussing CRML's strategic position with its Tanbreez project and significant international processing partnerships, anticipating its crucial role in securing critical mineral supply chains.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is trending as its "Intents" technology gains significant traction for seamless cross-chain interoperability, fostering partnerships with major protocols like Starknet and Sui. The community is actively discussing NEAR's potential as an "invisible engine" for the agentic economy, leveraging its AI integration and chain abstraction capabilities. This highlights growing real-world utility and an undervalued perception within the crypto space.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug

FDA approval of NVO's oral Wegovy could reshape obesity care and lift healthcare ETFs, offering investors diversified exposure to the GLP-1 boom.

6 Top-Performing ETF Areas of Last Week 

Cannabis, metals, space and health care led ETF gains last week. WEED, CNBS, SIL, UFO, GDXJ, PLTM and OZEM outperformed despite tech weakness.

Best-Performing ETFs of November 

November muted for markets, but ETFs like SPYM, BWET, WNTR, LITP and OZEM stand out.

Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in 

Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.


Novo Nordisk A/S (NVO) shares slid 3% in the early premarket session on Monday as the Ozempic and Wegovy weight-loss drugmaker snagged a&nbsp;bearish recommendation from a Wall Street firm.&nbsp;Morgan Stanley analyst downgraded&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk stock</a> to ‘Underweight’ from ‘Equal Weight’ and also reduced the price target for the stock to $47 from $59, the excerpts of the note published by The Fly showed. Morgan Stanley’s updated price target implies a nearly 13% downside from the stock’s Friday close.The stock was among the top five trending equity tickers on Stocktwits early Monday. Retail sentiment toward the stock, however, remained ‘extremely bullish’ (76/100), and the message volume on the stream was ‘high.’<figure class="image"><img style="aspect-ratio:619/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_5_23_05_AM_png_5def6a683f.webp" alt="Screenshot 2025-09-29 at 5.23.05 AM.png" width="619" height="53"><figcaption>NVO sentiment and message volume as of 5:20 a.m. ET, Sept. 29 | source: Stocktwits</figcaption></figure>Morgan Stanley attributed its negative thesis on the Danish company to its view that the weight loss prescription growth in the U.S. would slow down amid competitive pressures. According to the firm, this would drive downside revisions to the 2026 and 2027 consensus estimates for Novo Nordisk.&nbsp;Analysts at the firm said the lack of momentum in U.S. prescriptions for Wegovy, Ozempic and Rybelsus makes it cautious on the company's short-term growth profile. Additionally, the analyst noted that the lack of catalysts exacerbates the downside risk profile over the next six months.A New York Times report stated last week that the company was cutting jobs following the profit warning it issued in late July.&nbsp;Novo Nordisk stock has lost over 34% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-analyst-says-i-phone-s-worst-period-in-china-has-passed/chDMvs4R378">Apple Analyst Says ‘iPhone’s Worst Period In China Has Passed’ — The Xiaomi Data That Adds Strength To Bull Case For Cupertino</a>

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Why Wegovy Maker Novo Nordisk’s Stock Is Sliding 3% Premarket Today

Morgan Stanley attributed its negative thesis on the Danish company to its view that the weight loss prescription growth in the U.S. would slow down amid competitive pressures.

Equity

Morgan Stanley attributed its negative thesis on the Danish company to its view that the weight loss prescription growth in the U.S. would slow down amid competitive pressures.



NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend. 

ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Eli Lilly shares rose more than 1% premarket Thursday, on track to hit levels last seen in late October, as the pharmaceutical giant posted stronger-than-expected earnings and revenue despite another sales miss for its obesity and diabetes drugs.The company reported Q4&nbsp;earnings per share (EPS) of $5.32, beating the $5.08 consensus estimate, while revenue came in at $13.53 billion, topping Wall Street’s $13.43 billion forecast.&nbsp;Sales of its blockbuster GLP-1 drugs Zepbound and Mounjaro surged but came in slightly below expectations, weighed down by lower realized prices.&nbsp;Mounjaro generated $3.53 billion in revenue, a 60% jump from the prior year but short of analysts’ $3.62 billion estimate. Zepbound posted $1.91 billion in sales, missing the $1.98 billion forecast.&nbsp;This marks the second consecutive quarter where both drugs have fallen short of estimates, according to <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/02/06/eli-lilly-lly-earnings-q4-2024.html">CNBC</a>.Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.&nbsp;CEO David Ricks called 2024 a highly successful year, highlighting major clinical readouts for tirzepatide in treating chronic diseases tied to obesity, billions in manufacturing expansion, and the launch of Alzheimer’s drug Kisunla and dermatitis medication Ebglyss as key drivers of long-term growth.&nbsp;“We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth,” he added.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Eli_Lilly_sentiment_and_message_volume_Feb_6_premarket_0e4b15d3e8.png" alt="Eli Lilly sentiment and message volume Feb 6 premarket.png" width="1318" height="324"><figcaption>Eli Lilly sentiment and message volume Feb 6 premarket as of 8 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, Eli Lilly was among the top 10 trending tickers ahead of Thursday’s opening, with sentiment turning more bullish.&nbsp;Optimistic traders pointed to the earnings beat and expected continued strength, with one eyeing a move past $900.&nbsp;<stembedurl>https://stocktwits.com/Zukio/message/603106677</stembedurl>Another said hedge funds and institutional investors would likely drive the&nbsp;actual move during market hours.<stembedurl>https://stocktwits.com/nat9co/message/603108641</stembedurl>For 2025, Eli Lilly expects EPS between $22.50 and $24.00, compared to the $22.69 consensus estimate, and projects revenue between $58 billion and $61 billion, surpassing Wall Street’s $58.91 billion forecast.&nbsp;The company is ramping production to meet soaring demand, estimating it will manufacture at least 1.6 times the number of incretin doses in the first half of 2025 compared to a year ago.&nbsp;Lilly also announced plans to report late-stage data for its next-generation obesity drug retatrutide later this year, ahead of schedule.As of Wednesday’s close, <a href="https://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> was up nearly 8% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat

Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.

Eli Lilly &amp; Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6%&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lly-stock-falls-on-q4-weight-loss-drug-sales/chG8mwrRVc">plunge</a> — the worst session for the stock in nearly four years.&nbsp;The selloff followed the drugmaker's disappointing fourth-quarter (Q4) revenue guidance, with significant misses in sales for its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound.However, several Wall Street analysts expressed optimism, suggesting the dip could offer an attractive entry point for investors.Leerink noted Lilly lowered its Q4 revenue guidance by 5% but issued a 2025 revenue forecast 2% above its consensus, according to The Fly. The brokerage maintained its 'Outperform' rating, citing long-term growth potential and a promising pipeline.BofA Securities reiterated a 'Buy' rating with a $997 price target,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/stock-market-news/eli-lilly-bofa-says-buy-the-dip-after-shares-slide-on-q4-miss-3813128">according</a> to Investing.com. Analyst Tim Anderson emphasized that despite short-term challenges, Lilly remains a dominant player in the "diabesity" market with significant growth opportunities.JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity, highlighting Lilly's strong 2025 positioning, expanded market presence, and anticipated 60% growth in sellable doses of incretins in the first half of 2025.Mizuho's Jared Holz&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.google.com/search?q=eli+lilly+mizuho&amp;oq=eli&amp;gs_lcrp=EgZjaHJvbWUqBggAEEUYOzIGCAAQRRg7MgYIARBFGDsyBggCEEUYOzITCAMQLhiDARjHARixAxjRAxiABDIGCAQQRRg5MgYIBRBFGDwyBggGEEUYPDIGCAcQRRg90gEINjAxMGowajeoAgCwAgA&amp;sourceid=chrome&amp;ie=UTF-8">told</a> CNBC that "some of the supply commentary from the company makes a lot of sense" and highlighted the nascent stage of the obesity market. However, he flagged valuation as a concern, with Lilly trading at 32 times 2025 earnings estimates—higher than most large-cap pharma peers.Retail message volume on Stocktwits about Lilly jumped over 240% on Tuesday.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/LLY_sentiment_and_message_volume_Jan_15_premarket_8c6741e2bb.png" alt="LLY sentiment and message volume Jan 15 premarket.png" width="1318" height="324"><figcaption>LLY sentiment and message volume Jan 15 premarket as of 8 am ET | source: Stocktwits</figcaption></figure>Heading into Wednesday, sentiment on the platform remained 'bullish,' as watchers took cues from analyst optimism and kept faith in long-term prospects for Lilly's weight-loss and diabetes drugs remain intact.<a href="https://stocktwits.com/symbol/LLY">Eli Lilly's stock</a> is down 4.5% year-to-date but has gained over 16% in the past 12 months. The company will report fourth-quarter and full-year results next month.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish

JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity.

Current Price	$36.20
Prev Close	$35.38
Open	$35.75
Dividend Yield	N/A
50-Day Moving Average	$33.49
Beta	N/A
Avg. Volume	22,153.50
PE Ratio	N/A

52-Week High	$36.49
52-Week Low	$20.01
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

OZEM
Roundhill GLP-1 & Weight Loss ETF

Feed

News

Sentiment

Fundamentals

Info

Latest OZEM News

OZEMRoundhill GLP-1 & Weight Loss ETF